Comprehensive Analysis of Barrett's Esophagus: Focused on Carcinogenic Potential for Barrett's Cancer in Japanese Patients.
Barrett’s esophagus
Columnar-lined epithelium
Esophageal adenocarcinoma
Next-generation sequence
p53
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
17
06
2020
accepted:
12
08
2020
pubmed:
26
8
2020
medline:
23
9
2021
entrez:
26
8
2020
Statut:
ppublish
Résumé
Barrett's esophagus (BE) is a precursor of esophageal adenocarcinoma (EAC). Therefore, an accurate diagnosis of BE is important for the subsequent follow-up and early detection of EAC. However, the definitions of BE have not been standardized worldwide; columnar-lined epithelium (CLE) without intestinal metaplasia (IM) and/or < 1 cm is not diagnosed as BE in most countries. This study aimed to clarify the malignant potential of CLE without IM and/or < 1 cm genetically. A total of 96 consecutive patients (including nine patients with EAC) who had CLE were examined. Biopsies for CLE were conducted, and patients were divided into those with IM and > 1 cm (Group A) and those without IM and/or < 1 cm (Group B). Malignant potential was assessed using immunochemical staining for p53. Moreover, causative genes were examined using next-generation sequencing (NGS) on ten patients without Helicobacter pylori infection and without atrophic gastritis. Of the 96 patients, 66 were in Group B. The proportion of carcinoma/dysplasia in Group A was significantly higher than that in Group B (26.7% in Group A and 1.5% in Group B; p < 0.01). However, one EAC patient was found in Group B. In the immunostaining study for non-EAC patients, an abnormal expression of p53 was not observed in Group A, whereas p53 loss was observed in three patients (4.6%) in Group B. In the NGS study, a TP53 mutation was found in Group B. CLE without IM and/or < 1 cm has malignant potential. This result suggests that patients with CLE as well as BE need follow-up.
Sections du résumé
BACKGROUND/AIM
Barrett's esophagus (BE) is a precursor of esophageal adenocarcinoma (EAC). Therefore, an accurate diagnosis of BE is important for the subsequent follow-up and early detection of EAC. However, the definitions of BE have not been standardized worldwide; columnar-lined epithelium (CLE) without intestinal metaplasia (IM) and/or < 1 cm is not diagnosed as BE in most countries. This study aimed to clarify the malignant potential of CLE without IM and/or < 1 cm genetically.
METHOD
A total of 96 consecutive patients (including nine patients with EAC) who had CLE were examined. Biopsies for CLE were conducted, and patients were divided into those with IM and > 1 cm (Group A) and those without IM and/or < 1 cm (Group B). Malignant potential was assessed using immunochemical staining for p53. Moreover, causative genes were examined using next-generation sequencing (NGS) on ten patients without Helicobacter pylori infection and without atrophic gastritis.
RESULT
Of the 96 patients, 66 were in Group B. The proportion of carcinoma/dysplasia in Group A was significantly higher than that in Group B (26.7% in Group A and 1.5% in Group B; p < 0.01). However, one EAC patient was found in Group B. In the immunostaining study for non-EAC patients, an abnormal expression of p53 was not observed in Group A, whereas p53 loss was observed in three patients (4.6%) in Group B. In the NGS study, a TP53 mutation was found in Group B.
CONCLUSION
CLE without IM and/or < 1 cm has malignant potential. This result suggests that patients with CLE as well as BE need follow-up.
Identifiants
pubmed: 32840705
doi: 10.1007/s10620-020-06563-1
pii: 10.1007/s10620-020-06563-1
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2674-2681Informations de copyright
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Spechler SJ, Goyal RK. Barrett’s esophagus. N Engl J Med. 1986;315:362–371.
doi: 10.1056/NEJM198608073150605
Barrett NR. The lower esophagus lined by columnar epithelium. Surgery. 1957;41:881–894.
pubmed: 13442856
Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146.
doi: 10.1093/jnci/dji024
Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009;136:376–386.
doi: 10.1053/j.gastro.2008.12.015
Caygill CP, Royston C, Charlett A, et al. Mortality in Barrett’s esophagus: three decades of experience at a single center. Endoscopy. 2012;44:892–898.
doi: 10.1055/s-0032-1309842
Shaheen NJ, Falk GW, Iyer PG, et al. American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol. 2016;111:30–50.
doi: 10.1038/ajg.2015.322
Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11th Edition. Esophagus. 2017; 14: 37–65.
Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–1057.
doi: 10.1093/jnci/djr203
Younes M, Brown K, Lauwers GY, et al. p53 protein accumulation predicts malignant progression in Barrett’s metaplasia: a prospective study of 275 patients. Histopathology. 2017;71:27–33.
doi: 10.1111/his.13193
Younes M, Ertan A, Lechago LV, et al. P53 Protein accumulation is a specific marker of malignant potential in Barrett’s metaplasia. Dig Dis Sci. 1997;42:697–701. https://doi.org/10.1023/A:1018828207371 .
doi: 10.1023/A:1018828207371
pubmed: 9125634
Contino G, Vaughan TL, Whiteman D, et al. The evolving genomic landscape of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2017;153:657–673.
doi: 10.1053/j.gastro.2017.07.007
Stachler MD, Camarda ND, Deitrick C, et al. Detection of mutations in Barrett’s esophagus before progression to high-grade dysplasia or adenocarcinoma. Gastroenterology. 2018;155:156–167.
doi: 10.1053/j.gastro.2018.03.047
Amano Y, Ishimura N, Furuta K, et al. Which landmark results in a more consistent diagnosis of Barrett’s esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc. 2006;64:206–211.
doi: 10.1016/j.gie.2006.04.029
Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The Updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Pathol. 1996;20:1161–1181.
doi: 10.1097/00000478-199610000-00001
Timmer MR, Martinez P, Lau CT, et al. Derivation of genetic biomarkers for cancer risk stratification in Barrett’s oesophagus: a prospective cohort study. Gut. 2016;65:1602–1610.
doi: 10.1136/gutjnl-2015-309642
Thota PN, Vennalaganti P, Vennelaganti S, et al. Low risk of high-grade dysplasia or esophageal adenocarcinoma among patients with Barrett’s esophagus less than 1 cm (irregular z line) within 5 years of index endoscopy. Gastroenterology. 2017;152:987–992.
doi: 10.1053/j.gastro.2016.12.005
Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study. Am J Gastroenterol. 2011;106:1447–1455.
doi: 10.1038/ajg.2011.130
Streppel MM, Lata S, DelaBastide M, et al. Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett’s esophagus. Oncogene. 2014;33:347–357.
doi: 10.1038/onc.2012.586
Rabinovitch PS, Reid BJ, Haggitt RC, et al. Progression to cancer in Barrett’s esophagus is associated with genomic instability. Lab Invest. 1988;60:65–71.
Yokoyama A, Kakiuchi N, Yoshizato T, et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature. 2019;565:312–317.
doi: 10.1038/s41586-018-0811-x
Altaf K, Xiong JJ, la Iglesia D, et al. Meta-analysis of biomarkers predicting risk of malignant progression in Barrett’s oesophagus. Br J Surg. 2017;104:493–502.
doi: 10.1002/bjs.10484